MarTempo

MarTempo is a biotechnology company focused on developing first-in-class small molecule therapeutics that target the molecular machinery of the circadian clock. The company's research centers on modulating Cryptochrome proteins (CRY1 and CRY2), which are essential regulators of the body's internal timing system and influence metabolic, inflammatory, and growth pathways. By leveraging deep structural biology insights, MarTempo aims to address diseases driven by circadian dysfunction, including metabolic syndrome, certain cancers, and inflammatory conditions. The company was founded by leading experts in chronobiology and structural biology to translate academic breakthroughs into precision medicines. MarTempo's platform enables the discovery of potent and selective modulators of core clock components to restore physiological balance. This approach represents a novel frontier in treating chronic diseases by synchronizing cellular processes with the body's natural rhythms.